3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
152
Neoplasm Metastasis
22
Neoplasms
21
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
belzutifan
4
gallium Ga 68 dotatate
3
Everolimus
2
vatalanib
1
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Vorinostat
1
Sunitinib
1
Ranibizumab
1
Propranolol
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorodeoxyglucose F18
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
von Hippel-Lindau Disease
×
palbociclib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled